Carma Fund

Carma Fund operates as an early-stage investment fund for Life Science and Healthcare technologies, strategically deploying capital into promising startups and academic projects across Europe, particularly Germany. The fund accelerates the translation of scientific discoveries into practical, innovative medical solutions, guiding them from foundational research to market.

Established in 2022, Carma Fund was co-founded by Christian Leikert and Martin Raditsch. The fund’s inception stemmed from the insight that a dedicated investment vehicle was needed to bridge the gap between scientific breakthroughs and clinical application. Key initiators like Ascenion and Goethe University supported this vision for translational research.

Carma Fund primarily supports early-stage companies and academic spin-offs within the life science and healthcare sectors. Its mission is to cultivate novel medical solutions addressing unmet patient needs. The fund’s long-term vision aims to accelerate transformative scientific advancements, thereby contributing to public health and improving patient outcomes.